Daraxonrasib (RMC-GI-102) plus gemcitabine and nab-paclitaxel - (RASolute 303)

June 24, 2026: Revolution Medicines announced four presentations on its RAS(ON) pipeline at the 2026 ESMO Gastrointestinal Cancers Congress (July 1–4, 2026; Munich).

Zoldonrasib (RMC-9805; RAS(ON) KRAS G12D-selective covalent inhibitor) Phase 1/2 combination trials in metastatic pancreatic ductal adenocarcinoma (mPDAC):

• Oral presentation (#340O, July 2, 2:40–2:50 p.m. CEST): Safety and efficacy of zoldonrasib plus chemotherapy in first-line RAS G12D mPDAC.
• Oral presentation (#341O, July 2, 2:50–3:00 p.m. CEST): Safety and efficacy of zoldonrasib plus daraxonrasib (RMC-6236) in 2L+ KRAS G12D mPDAC.

Daraxonrasib (RMC-6236; oral RAS(ON) multi-selective inhibitor) Phase 3 trials-in-progress posters in PDAC:

• RASolute 303 (#471TiP, July 3, 3:30–4:30 p.m. CEST): Global randomized 3-arm study of daraxonrasib monotherapy or daraxonrasib + gemcitabine/nab-paclitaxel vs gemcitabine/nab-paclitaxel as first-line treatment for metastatic PDAC.
• RASolute 304 (#472TiP, July 3, 3:30–4:30 p.m. CEST): Randomized study of adjuvant daraxonrasib vs observation after completion of neoadjuvant and/or adjuvant chemotherapy in resected PDAC.